News | February 20, 2022
Syncona completes sale of Gyroscope to Novartis
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Subscribe To Our Newsletter & Stay Updated
